Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I wonder whether some big holder may have been determined to sell into the mid 20s to account for the volume that has been shifted without a massive swing I'm share price. Hopefully that seller is now done and the handbrake can come off.
Yes very muted response given the potential health benefits from this product
Abstract
The gut microbiota and their metabolites could play an important role in health and diseases of human beings. Short-chain fatty acids (SCFAs) are mainly produced by gut microbiome fermentation of dietary fiber and could also be produced by bacteria of the skin and vagina. Acetate, propionate, and butyrate are three major SCFAs, and their bioactivities have been widely studied. The SCFAs have many health benefits, such as anti-inflammatory, immunoregulatory, anti-obesity, anti-diabetes, anticancer, cardiovascular protective, hepatoprotective, and neuroprotective activities. This paper summarizes health benefits and side effects of SCFAs with a special attention paid to the mechanisms of action. This paper provides better support for people eating dietary fiber as well as ways for dietary fiber to be
AqSu, thanks for posting.
Things are even better for sweetbiotix than relayed in the latest RNS. Having spotted there was no mention of the standalone sweetbiotix product referred to in the sweetbiotix update RNS less than a month ago, I posed the following question and received the response below.
"One question regarding the sweetbiotix statement "The Company has included SweetBiotix® in a finished product for a large global partner with a view for an upcoming launch. The Company hopes to see SweetBiotix® in an increasing number of products launched throughout 2024." Does this mean that there is no longer an intention to first launch sweetbiotix as a direct bulk sugar replacement as announced in the sweetbiotix update less than one month ago?
"Discussions are ongoing but are likely to involve a phased introduction of SweetBiotix® products as a direct bulk sugar substitute and then introduced into OptiBiotix's and partners consumer products across an increasing range of applications. "
Response from SOH
"We still intent to launch sweetbiotix as a bulk sugar replacement. These two approaches are not mutually exclusive. We have been surprised and somewhat pleased that progress has been made so quickly with a large corporate in terms of inclusion in a final product."
So two shots at goal :)
A six figure payemt to be made every 12 months nail product launch? How many 12 month periods are they expecting to wait until product launch? What payments would be expected after product launch?
DC, no it's not you. It's everyone else! Lol, wink emoji.
As you saw, yesterday's RNS was to update progress on 1st generation products. So for me, it was a nice surprise to see an exciting snippet about Sweet, at the end of the lengthy announcement. I hope it wasn't SOH teasing us and that the launch of 2nd generation products is truly imminent. And, that we will get separate, "transformational" updates on Sweet. Cheers. MU.
PS: let's hope in this leap year, the SP does a big leap. Up!
I was thinking the same. The volume though tells a different story than the share price which is even wierder. Huge volume both days with very little share price movement today.
Very odd
I can't understand the muted response to yesterdays Sweetbiotix news. Surely the numbers we're seeing here will lead to staggering revaluation of the company? procurementresource.com/resource-center/stevia-price-trends
Is it me, am I missing something obvious?
Original US sweetbiotix deal -
OptiBiotix will receive a modest six-figure payment from the Company on signing the agreement and at 12 monthly intervals until product launch. Additional similar payments will be due on product launch plus royalties on all future product sales.
Does this mean another payment on the launch of the first sweetbiotix product?
Our FD (albeit part-time) was only appointed on 4th Dec 2023
https://www.optibiotix-ir.com/content/news/archive/2023/041223
but now also noted on website
https://optibiotix.com/corporate/
albeit i accept an update to the revenue potential from May 2023 slides , prior to his appointment, would be more than useful - but give him a bit more time!
slides here - which at time of release i noted underwhelming for 2024 and even 2025
https://www.walbrookpr.com/docs/librariesprovider48/default-document-library/investors/optibiotix---investor-presentation-may-2023.pdf
just reminding the bb re the only figures we have to date - again as far as i'm aware
mol
Evening all
a positive step forward indeed and further improvement on the last rns only c 3 weeks ago
https://www.optibiotix-ir.com/content/news/archive/2024/300124
a reminder from May 2023 presentation and deals signed - albeit nothing since on dsm-firmenich % royalty, as far as i'm aware, unlike US partner
SweetBiotix: A portfolio of sweet low-calorie fibres created by combining prebiotic functional fibres and modified mogrosides or steviol glycosides in a single enzymatic step
Commercial Status:
i. Manufacturing agreement signed with US partner September 2020 for mogroside product
i. Scale up optimization completed/optimised products received December 2022 as liquid, freeze dried in May
ii. Partner taste testing confirms product acceptability. Analytical testing and structural analysis underway
iii. Structural analysis underway to determine novelty and the regulatory pathway
iv. Independent peer reviewed publication confirms sweetness and prebiotic functionality highlighting health benefits – start of marketing
v. Six figure annual milestone paid during scale up plus six figure launch milestone
vi. Royalties 5% plus a further 5% on 11 named companies( Kelloggs, Nestle, Coca Cola ,Firmenich, Tereos, Cargill, Arla ,Tate and Lyle, Agropur, Givaudan, Tata)
ii. Agreement signed with Firmenich July 2022 for stevia glycoside product
i. Manufacturing agreement signed and project progressing rapidly
ii. Manufacturing scale up underway, product produced and tested, process optimization underway to enhance yield
iii. Payments: Six figure payment per market approval (USA/Europe/Asia) - potential H2 2023/H1 2024
iv. One off six figure milestone when reaching $5m and $12m sales plus royalties on all sales
Next Steps:
Structural and functional analysis, regulatory approvals, partner application development and launch discussions
which more or less is noted in
https://www.optibiotix-ir.com/content/news/archive/2023/190723
mol
The statement read > 100k tonnes
Opti will make a big chunk even on 10k tonnes.
This is starting to look very interesting.
If theses numbers come through. 100k metric tonnes per annum, from 'ONE' of its SweetBiotix® partners.
Mind blowing.
OK no financials but the big big takeaway is absolute confirmation of product launch with sweetbiotix and more on the way this year.The launch of a sweetener of this type is actually perfect timing.Reports of the adverse effects of artificial sweeteners on the gut microbiome means the traditional sweeteners are on the way out and hopefully sweetbiotix is the one the industry goes for and then its game on and a complete transformation of the company is about to happen.The science is there and fits the criteria the big companies are after and we must assume after all this time they have got the taste right and the Stevia aftertaste is history.
I will not be surprised if governments start to legislate against standard artificial sweeteners and there will then be a rapid switch to prebiotic sweeteners and we are led to believe we are a leading light so this could be the moment we have waited a long time for.
It won't be too long before Stephen is plumping up this company for a sale so if I was younger I would tuck the shares away and forget about them for a while.I think this confirmation will be the start of a steady rise until the product arrives but we will have to see on that one.
Thats per year as well. Imagine how much end product that will make. Isn’t it “tiered “ revenue as well, where Opti receive multiple streams from manufacturer/ingredients/retailers?
Slimbiome fibres retail at £30k per tonne
Yes, the fact that we are about to go on the shelves with Sweet is huge. It means the final tests on taste and shelf life.
Plus I would love if anyone had some insight into what the tonnage of Sweet Firmenech are projecting is worth to hs.
The spoonful of sugar was hidden at the end and was possibly the most important part.
Very wordy as usual. Plenty of %s. Some perhaps more useful tonnages. Have to wait for revenues. But it was a pretty positive update.
Overall I'm pleased to have this update than nothing at all. Fingers crossed SweetBiotix is really imminent
A reminder of the stated aim for each B/U to be profitable at least on a month by month basis by end 2023; From 2023 Aug Commercial Update; “Stephen O'Hara, CEO of OptiBiotix Health plc said: "We are making good progress on our aims of getting existing partners returning to forecast, bringing in new partners, particularly in the USA and Asia, and expanding e-commerce channels to grow online sales and reduce partner dependency. This is all part of plans for each business unit (USA, India, Ecommerce, B2B) to reach operational profitability, at least on a monthly basis by the end of the calendar year.”
So at the very least we should have been provided with the position for each B/U but we were only told about one B/U, e-commerce "E-commerce sales for 2023 were 287% up on 2022 driven by strong growth in China of gummies and large increases in Amazon Prime subscriptions. This progress led the consumer health business to profitability in October and November 2023". We know the first meaningful US order slipped into 2024 so probably mainly the royalty payment from the US partner circa £85K in 2023 for sweetbiotix. Any H&B and THG sales percentage increases are coming off a very low base, 2022 figures with a rough guess of how much to reduce regional sales for to allow for PBX sales inclusion are as follows;
Probiotix £24,000.00
Functional Fibres £433,000.00
TOTAL £457,000.00
Functional fibres by Region
UK (minus est £5000 PBX sales) £127,000.00
India £61,000.00
ROW (minus est £4000 pbx sales) £160,000.00
US (minus est £15000 PBX sales) £85,000.00
TOTAL £433,000.00
On the plus side, and it is a big plus, 2024 looks to be much healthier and the launch of sweetbiotix will be a game changer
The last paragraph on Forward Looking Statements is a particularly strong get out of gaol free but necessary statement
Classic SOH, percentages hiding actual revenue, or god forbid, profit numbers and full to the brim with if, buts and maybes. You gotta laugh.
Skid35,
OPTI could report sales numbers for the whole corp for 2023 like normal companies do in the Jan / Feb trading updates. Instead its 2 pages of inconsistent information.
Bean - as partners are named I expect that there are confidentiality cause preventing absolute £ being stated. The % measure as you state is deliberately and contractually necessarily ambiguous.
Overall a positive update i) does appear they are getting traction and ramping ii) although an old codger myself does appear that their marketing is now more relevant using social media channels iii) Sweet a complete game changer - any concrete news will have this 3-4x.
Davey
The new part time CFO at Opti needs to step up.
Providing an overall unaudited revenue number for year would be a very useful addition to this word salad of random percentage increases, indications of monthly revenue of £20,000 to £50,000 per month in China Ecoomerce and stock taken of £417,000.
Reading between the lines it looks like revenue and gross margins will be up but by how much and what to - I couldn’t begin to make an estimate and that is poor.
Many of the UKs largest groups and all the major banks have published their full audited Dec 2023 results and yet Opti can’t tell us unaudited revenue.